Navigation Links
Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis
Date:11/2/2009

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010. When asked why they would prescribe the drug, more than 60 percent of these rheumatologists cite the fact that, in clinical trials, Actemra has exhibited efficacy comparable to the efficacy demonstrated in separate trials for TNF-alpha inhibitors such as Amgen/Pfizer's Enbrel and Abbott's Humira, the two leading agents in the rheumatoid arthritis drug market.

The new Physician & Payer Forum report entitled The Rheumatoid Arthritis Biologics Landscape: Differentiation and Reimbursement in a Crowded Market finds that the majority of surveyed rheumatologists indicate that they will welcome the availability of Actemra because interleukin inhibition represents a promising novel mechanism of action in rheumatoid arthritis treatment. The report also finds that the market potential for novel oral agents such as Pfizer's CP-690550 is significant as, on average, surveyed rheumatologists estimate that more than half of patients treated with conventional disease-modifying antirheumatic drugs fail treatment and require subsequent therapy with a different drug class.

"More than two-thirds of surveyed rheumatologists expect that the majority of patients who require therapy with a disease-modifying antirheumatic drug would choose oral dosing over subcutaneous delivery," said Decision Resources Analyst Joanna Kim, M.Ed.

If CP-690550 were priced at a discount of greater than 35 percent as compared with Humira, more than half of surveyed managed care organizations' (MCOs) pharmacy directors would assign CP-690550 to tier 2 of their formularies. The report also finds that, with regard to Actemra, 75 percent of surveyed MCOs indicate that they will likely cover Actemra while 80 percent and 85 percent of surveyed MCOs expect to cover its competitors, Genmab/GlaxoSmithKline's Arzerra and Biogen Idec/Roche's ocrelizumab, respectively.

The Rheumatoid Arthritis Biologics Landscape: Differentiation and Reimbursement in a Crowded Market is based on a U.S. survey of 100 rheumatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

Webinar

Media members are welcome to attend our upcoming webinar entitled Actemra and CP-690550 in Rheumatoid Arthritis: Can a Novel Agent Revolutionize Established Treatment Patterns? This webinar will be held on November 18, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at ccomfort@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources          Decision Resources, Inc.
    Christopher Comfort         Elizabeth Marshall
    781-296-2597                781-296-2563
    ccomfort@dresources.com     emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
2. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
5. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
6. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
7. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
10. High Blood Pressure May Heighten Effects of Alzheimers Disease
11. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
(Date:2/23/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... release fourth quarter and yearly financial results after ... management will host an investment-community conference call at ... on March 2 nd 2017 to discuss ...
(Date:2/23/2017)... , February 23, 2017 ... from increasing caseload for varicose veins in their body. ... globe are prompting the adoption of endovenous laser therapy ... global endovenous laser therapy market, published by ... of lifestyle choices and consequences of obesity have collectively ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... York (PRWEB) , ... February 23, 2017 , ... Curemark, ... the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now ... clinical sites already enrolling children across the United States. , “There are currently ...
Breaking Medicine News(10 mins):